[NEW PODCAST] Exploring the FDA's Draft Guidance on Psychedelic Drug Research


Unlocking New Horizons

The FDA recently published a first-ever draft guidance on clinical development requirements for psychedelic drugs. 

Join Altasciences’ panel of experts as they provide an in-depth review of the guidance and valuable insights into the areas where further methodological adaptations to study designs may be necessary. These adaptations play a pivotal role in accurately assessing the safety, pharmacology, and efficacy of groundbreaking psychedelic compounds developed for specific medical applications.


FDA Guidenace for Industry Psychedelic Drugs

You may also be interested in the following:

•    Webpage: CNS Drug Development Solutions
•    Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
•    Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics